Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av lifileucel (tumörinfiltrerande lymfocyter) hos vuxna med avancerad melanom

28 september 2026 uppdaterad av: Iovance Biotherapeutics, Inc.

En fas 2, multcenter, öppen studie av Lifileucel (tumörinfiltrerande lymfocyter [TIL]) hos deltagare med tidigare behandlad avancerad melanom

This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma

Studieöversikt

Status

Aktiv, inte rekryterande

Intervention / Behandling

Detaljerad beskrivning

This is a Phase 2 study of the lifileucel treatment regimen in participants who previously received treatment for unresectable or metastatic (advanced) melanoma with 1 prior line of an anti-programmed cell death protein-1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agent or whose melanoma progressed during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (early relapse). Participants who have BRAF V600 mutation positive melanoma may have received or refused 1 additional prior line treatment with a BRAF inhibitor

± a MEK inhibitor

Studietyp

Interventionell

Inskrivning (Beräknad)

24

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Queensland
      • Greenslopes, Queensland, Australien, 4120
        • Greenslopes Private Hospital
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Sarah Cannon Research Institute
    • Ontario, Canada
      • Toronto, Ontario, Canada, Kanada, M5G 2M9
        • Princess Margaret Cancer Centre
    • Quebec, Canada
      • Montral, Quebec, Canada, Kanada, H2X 0A9
        • Centre Hospitalier de l'Universite de Montreal
      • London, Storbritannien, SW3 6JJ
        • Royal Marsden Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 70 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
  • The participant has an ECOG performance status of 0 or 1 and an estimated life expectancy of > 6 months.
  • The participant must have experienced radiographic disease progression on: 1 prior line of an anti-PD-(L)1 treatment (as a monotherapy or as part of a combination) for advanced melanoma or during or within ≤ 12 weeks after adjuvant anti-PD-(L)1 treatment (as a monotherapy or as part of a combination). Participants who have BRAF V600 mutation positive melanoma may have received 1 additional prior line of treatment with a BRAF inhibitor ± a MEK inhibitor or choose lifileucel as an alternative option to a BRAF inhibitor ± a MEK inhibitor.
  • Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
  • Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
  • Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
  • Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
  • Participants must have adequate organ function.
  • Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.

Exclusion Criteria:

  • Participant has melanoma of uveal/ocular origin.
  • Participant has symptomatic untreated brain metastases.
  • Participant has active uveitis that requires active treatment.
  • Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
  • Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
  • Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
  • Participant has a history of allogeneic cell or organ transplant.
  • Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

Other protocol defined inclusion/exclusion criteria could apply.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Single Arm

Lifileucel

A tumor sample is resected from each patient for lifileucel manufacturing. Patients will first receive the preparative non-myeloablative lymphodepletion (NMA-LD) regimen. They will then receive the lifileucel infusion, followed by an abbreviated course of aldesleukin.

Andra namn:
  • LN-144

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Objective Response Rate
Tidsram: 12 months

To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators

12 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Complete Response Rate
Tidsram: 12 months

To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the investigators

12 months
Duration of Response
Tidsram: 12 months

To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the investigators

12 months
Disease Control Rate
Tidsram: 12 months

To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the investigators

12 months
Progression-Free Survival
Tidsram: 12 months

To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the investigators

12 months
Overall Survival
Tidsram: 18 months

To evaluate the efficacy of lifileucel as measured by OS

18 months
Adverse Events
Tidsram: 18 months

To demonstrate safety and tolerability of lifileucel

18 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

28 november 2025

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 juni 2028

Studieregistreringsdatum

Först inskickad

9 december 2025

Först inskickad som uppfyllde QC-kriterierna

15 december 2025

Första postat (Faktisk)

17 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera